CALC · CalciMedica, Inc.
$1.06
+0.04 (+3.92%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current operating plans, management believes its cash and cash equivalents may not be sufficient to fund its operations for a period of one year following the issuance of these financial statements. As a result, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$6.90M
Shares
6.83M
Volume · Oct 20
17.27K
Avg daily vol (35 sessions)
75.7K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.02
Open$1.03
Day$1.00–1.08
52W close$1.02–33.70
Avg vol 30d68K
Short int86K · 1.3% float · 1.5d
Short vol21%
Last earningsNov 7, 2025
DataJun 2023–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$21.24M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-277.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$18.62M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.3%
Latest settlement · 1.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−81%
below
Price vs 50-day avg
−51%
below
RSI (14)
17
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−45%
trailing
6-month return
−65%
trailing
YTD return
−97%
this year
Relative strength
−72%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+14% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.27% of float · ▼ -22.6% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
32 holders — near 3-yr high, broad support
Squeeze score
41
elevated · 0–100
Fundamentals
EPS growth
−61%
Y/Y
Free cash flow
$-21.2M
Quant / Vol
risk profile
Volatility
143%
annualized · 1-yr
Max drawdown
−97%
past year
ATR
14.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−81%
Bearish
Price vs 50-day avg
−51%
Bearish
RSI (14)
17
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+14% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.27% of float · ▼ -22.6% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
32 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $34
vs 200-day avg -81%
vs 50-day avg -51%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CALC
this stock
CalciMedica, Inc.
|
$6.90M | — | — | — | 1.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 16, 2026
- This year
- 24
CalciMedica, Inc. announced that on October 15, 2026, CFO Stephen Bardin provided notice of his resignation, effective following the filing of the Form 10-Q for the quarter ended September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CALC | -15.4% | -45.2% | -64.6% | -37.0% | -96.9% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -13.9% | -44.3% | -72.3% | -37.5% | -109.3% |